Cutaneous leishmaniasis in travellers: a focus on epidemiology and treatment in 2015. (Q38511211)

3 September 2017

title

Cutaneous leishmaniasis in travellers: a focus on epidemiology and treatment in 2015. (English)

1 reference

3 September 2017

main subject

cutaneous leishmaniasis

1 reference

2

Andrea K Boggild

1 reference

3 September 2017

Adrienne J Showler

1

1 reference

3 September 2017

publication date

1 July 2015

1 reference

Current infectious disease reports

3 September 2017

published in

1 reference

3 September 2017

volume

17

1 reference

3 September 2017

issue

7

1 reference

3 September 2017

page(s)

489

1 reference

GeoSentinel surveillance of illness in returned travelers, 2007-2011

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Travelers with cutaneous leishmaniasis cured without systemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Leishmaniasis in travelers: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Leishmaniasis, an emerging infection in travelers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Leishmaniasis in the United States: treatment in 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Leishmaniasis acquired by travellers to endemic regions in Europe: a EuroTravNet multi-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Cutaneous leishmaniasis in the returning traveler

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Cutaneous leishmaniasis in British troops following jungle training in Belize

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Old world leishmaniasis: an emerging infection among deployed US military and civilian workers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Successful diagnosis and treatment 50 years after exposure: is mucocutaneous leishmaniasis still a neglected differential diagnosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Interventions for Old World cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Randomized, double-blind, comparative clinical trial on the efficacy and safety of intralesional sodium stibogluconate and intralesional 7% hypertonic sodium chloride against cutaneous leishmaniasis caused by L. donovani

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Intralesional antimony for single lesions of bolivian cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Topical paromomycin with or without gentamicin for cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: A double-blind control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Topical treatment of American cutaneous leishmaniasis with paramomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Long-term efficacy of single-dose radiofrequency-induced heat therapy vs. intralesional antimonials for cutaneous leishmaniasis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Kabul, Afghanistan: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Efficacy of Miltefosine for the Treatment of American Cutaneous Leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Interventions for American cutaneous and mucocutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Efficacy of glucantime in the treatment of Old World cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Miltefosine for new world cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Treatment of imported New World cutaneous leishmaniasis in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Evaluation of treatment with pentamidine for cutaneous leishmaniasis in Suriname

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

The epidemiology and control of leishmaniasis in Andean countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Molecular diagnosis of leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Advances in leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Comparison of PCR assays for diagnosis of cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Non-invasive cytology brush PCR diagnostic testing in mucosal leishmaniasis: superior performance to conventional biopsy with histopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Detection and species identification of Leishmania DNA from filter paper lesion impressions for patients with American cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Cutaneous leishmaniasis: clinical aspect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Novel low-cost thermotherapy for cutaneous leishmaniasis in Peru

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Drug resistance in leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Clinical guidelines for the management of cutaneous leishmaniasis in British military personnel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Placebo-Controlled Clinical Trial of Sodium Stibogluconate (Pentostam) versus Ketoconazole for Treating Cutaneous Leishmaniasis in Guatemala

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Treatment response of cutaneous leishmaniasis due to Leishmania aethiopica to cryotherapy and generic sodium stibogluconate from patients in Silti, Ethiopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0489-2

Thermotherapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia

21 January 2018

1 reference

12 December 2020

Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial

1 reference

12 December 2020

Cutaneous leishmaniasis

1 reference

12 December 2020

Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia

1 reference

12 December 2020

Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis

1 reference

12 December 2020

New developments in diagnosis of leishmaniasis.

1 reference

12 December 2020

Healing of Old World cutaneous leishmaniasis in travelers treated with fluconazole: drug effect or spontaneous evolution?

1 reference

12 December 2020

A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment

1 reference

12 December 2020

Resistance to antimony and treatment failure in human Leishmania (Viannia) infection

1 reference

12 December 2020

Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis

1 reference

12 December 2020

Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials

1 reference

12 December 2020

Miltefosine (Impavido) for leishmaniasis

1 reference

12 December 2020

Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.

1 reference

12 December 2020

Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala

1 reference

12 December 2020

High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis

1 reference

12 December 2020

Cutaneous leishmaniasis

1 reference

12 December 2020

Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama.

1 reference

12 December 2020

Leishmania panamensis transmission in the domestic environment: the results of a prospective epidemiological survey in Santander, Colombia

1 reference

12 December 2020

Treatment of cutaneous leishmaniasis with localized current field (radio frequency) in Tabasco, Mexico.

1 reference

12 December 2020

Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.

1 reference

12 December 2020

The natural history of cutaneous leishmaniasis in Guatemala

1 reference

12 December 2020

Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis

1 reference

12 December 2020

Risk factors for mucosal manifestation of American cutaneous leishmaniasis

1 reference

12 December 2020

Monitoring toxicity associated with parenteral sodium stibogluconate in the day-case management of returned travellers with New World cutaneous leishmaniasis [corrected]

1 reference

12 December 2020

Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate.

1 reference

12 December 2020

Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala

1 reference

12 December 2020

Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil--an area of Leishmania (V.) braziliensis transmission

1 reference

12 December 2020

Cutaneous leishmaniasis. Treatment with combined cryotherapy and intralesional stibogluconate injection

1 reference

12 December 2020

10.1007/S11908-015-0489-2

Identifiers

DOI

1 reference

3 September 2017

1 reference